early stage breast cancer
Oncology · 2017–2017
1decision
1medicine
1carried consumer input
0individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| pegfilgrastim Primary prophylaxis for febrile neutropenia in patients with early stage breast cancer being treated with docetaxel and cyclophosphamide. | Jul 2017 | Deferred | input received Medical Oncology Group |
Who spoke
Medical Oncology Group
What the PBS pays
$4M in government benefit over 2024–25, across 33,232 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| pegfilgrastim | $4.3M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.